Vir Biotechnology, Inc. Increase (Decrease) in Accounts Payable
Vir Biotechnology, Inc. (VIR) reported Increase (Decrease) in Accounts Payable of $8.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-05
- Vir Biotechnology, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $12.31M, a 38.94% increase year-over-year.
- Vir Biotechnology, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$4.23M.
- Vir Biotechnology, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $2.96M.
- Vir Biotechnology, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$5.40M, a 273.92% decline year-over-year.
- Vir Biotechnology, Inc. increase (decrease) in accounts payable for fiscal 2025 was $5.00M.
- Vir Biotechnology, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$988.00K, a 234.97% decline from fiscal 2023.
- Vir Biotechnology, Inc. increase (decrease) in accounts payable for fiscal 2023 was $732.00K, a 8.16% decline from fiscal 2022.
- Vir Biotechnology, Inc. increase (decrease) in accounts payable for fiscal 2022 was $797.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $8.08M 10-Q · filed 2026-08-05 | $11.04M derived: sum of 3 quarters · filed 2026-08-05 | $5.64M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$4.23M 10-Q · filed 2026-05-07 | -$1.27M derived: sum of 2 quarters · filed 2026-05-07 | -$6.67M derived: sum of 3 quarters · filed 2026-05-07 | $2.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$2.45M derived: sum of 2 quarters · filed 2026-02-23 | $6.41M derived: sum of 3 quarters · filed 2026-08-05 | $5.00M 10-K · filed 2026-02-23 |
| 2025-09-30 | -$5.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.46M derived: sum of 2 quarters · filed 2026-08-05 | $2.04M 10-Q · filed 2025-11-05 | $106.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $8.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $7.44M 10-Q · filed 2026-08-05 | $5.51M derived: sum of 3 quarters · filed 2026-08-05 | $8.61M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$1.42M 10-Q · filed 2026-05-07 | -$3.35M derived: sum of 2 quarters · filed 2026-05-07 | -$245.00K derived: sum of 3 quarters · filed 2026-05-07 | -$3.14M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.17M derived: sum of 2 quarters · filed 2026-02-23 | -$1.72M derived: sum of 3 quarters · filed 2026-02-23 | -$988.00K 10-K · filed 2026-02-23 |
| 2024-09-30 | $3.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $213.00K derived: sum of 2 quarters · filed 2025-11-05 | $948.00K 10-Q · filed 2025-11-05 | $3.58M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | -$2.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$2.16M 10-Q · filed 2025-08-06 | $469.00K derived: sum of 3 quarters · filed 2026-02-23 | -$7.06M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $735.00K 10-Q · filed 2025-05-08 | $3.36M derived: sum of 2 quarters · filed 2026-02-23 | -$4.16M derived: sum of 3 quarters · filed 2026-02-23 | -$5.10M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $2.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$4.90M derived: sum of 2 quarters · filed 2026-02-23 | -$5.83M derived: sum of 3 quarters · filed 2026-02-23 | $732.00K 10-K · filed 2026-02-23 |
| 2023-09-30 | -$7.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$8.46M derived: sum of 2 quarters · filed 2024-11-04 | -$1.90M 10-Q · filed 2024-11-04 | $905.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$934.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $5.63M 10-Q · filed 2024-08-01 | $8.43M derived: sum of 3 quarters · filed 2025-02-27 | $3.98M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $6.56M 10-Q · filed 2024-05-03 | $9.36M derived: sum of 2 quarters · filed 2025-02-27 | $4.92M derived: sum of 3 quarters · filed 2025-02-27 | $3.53M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$1.65M derived: sum of 2 quarters · filed 2025-02-27 | -$3.03M derived: sum of 3 quarters · filed 2025-02-27 | $797.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | -$4.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$5.83M derived: sum of 2 quarters · filed 2023-11-03 | -$2.00M 10-Q · filed 2023-11-03 | -$1.22M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $2.44M 10-Q · filed 2023-08-04 | $3.23M derived: sum of 3 quarters · filed 2024-02-26 | -$2.66M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $3.83M 10-Q · filed 2023-05-08 | $4.62M derived: sum of 2 quarters · filed 2024-02-26 | -$1.27M derived: sum of 3 quarters · filed 2024-02-26 | $4.97M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $788.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$5.10M derived: sum of 2 quarters · filed 2024-02-26 | $1.15M derived: sum of 3 quarters · filed 2024-02-26 | -$171.00K 10-K · filed 2024-02-26 |
| 2021-09-30 | -$5.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $358.00K derived: sum of 2 quarters · filed 2022-11-03 | -$959.00K 10-Q · filed 2022-11-03 | -$2.79M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $6.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $4.93M 10-Q · filed 2022-08-09 | $3.10M derived: sum of 3 quarters · filed 2023-02-28 | $5.49M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$1.32M 10-Q · filed 2022-05-05 | -$3.15M derived: sum of 2 quarters · filed 2023-02-28 | -$765.00K derived: sum of 3 quarters · filed 2023-02-28 | -$15.05M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $552.00K derived: sum of 2 quarters · filed 2023-02-28 | -$13.73M derived: sum of 3 quarters · filed 2023-02-28 | -$790.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | $2.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$11.90M derived: sum of 2 quarters · filed 2021-11-04 | $1.04M 10-Q · filed 2021-11-04 | $1.58M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$14.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$1.34M 10-Q · filed 2021-08-05 | -$806.00K derived: sum of 3 quarters · filed 2022-02-28 | $455.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $12.94M 10-Q · filed 2021-05-06 | $13.48M derived: sum of 2 quarters · filed 2022-02-28 | $14.74M derived: sum of 3 quarters · filed 2022-02-28 | $12.74M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $536.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.80M derived: sum of 2 quarters · filed 2022-02-28 | -$199.00K derived: sum of 3 quarters · filed 2022-02-28 | $964.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | $1.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$735.00K derived: sum of 2 quarters · filed 2020-11-10 | $428.00K 10-Q · filed 2020-11-10 | -$806.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | -$833.00K 10-Q · filed 2020-08-11 | -$2.07M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | $1.16M 10-Q · filed 2020-05-12 | -$71.00K derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | -$1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $1.47M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $2.71M 10-Q · filed 2019-11-19 | |||
| 2017-12-31 | $2.01M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |